Summary
Background Omalizumab is approved as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in patients with inadequate response to H1-antihistamine treatment. The urticaria control test (UCT) is a reliable, concise tool developed as an alternative to the 7-day urticaria activity score (UAS7) -the standard for CSU disease activity assessment. Objectives This prospective, open-label, phase IV study evaluated the efficacy and safety of omalizumab in French adult patients with CSU nonresponsive to H1-antihistamine treatment. Materials and methods Patients [n = 136; stratified 1 : 2 (with angiooedema : without angioedema)] received omalizumab 300 mg subcutaneously every 4 weeks for 12 weeks. Study assessments included UCT, UAS7, angiooedema activity score and D-dimer levels (exploratory objective). Results At Week 12, 74Á6% of the patients achieved disease control [UCT score ≥ 12 (primary endpoint)] and 67Á7% of patients showed well-controlled disease (UAS7 ≤ 6). There was a strong negative correlation between UCT score and UAS7 at Week 12 (Spearman's correlation coefficient À0Á839). Mean plasma D-dimer concentration was elevated at baseline (1002Á1 ng mL
À1
) and decreased notably at Week 8 (455 ng mL À1 ). Among the nine patients with a very high baseline D-dimer concentration (> 3000 ng mL
• The urticaria control test (UCT) is a recently validated tool for disease control assessment in patients with CSU.
• Elevated plasma levels of D-dimer observed in some patients with CSU suggests a potential role of D-dimer as a biomarker in CSU treatment response and prognosis.
What does this study add?
• Omalizumab controlled symptoms and improved quality of life in French patients with moderate-to-severe CSU.
• UCT was a reliable tool for the assessment of urticaria control.
• D-dimers are elevated in some patients with CSU and change in response to treatment with omalizumab.
• This study does not support the usefulness of D-dimer to monitor long-term disease prognosis in adult urticaria; however, it may indicate patients who respond to omalizumab.
Chronic spontaneous urticaria (CSU) is characterized by the spontaneous occurrence of transient, itchy recurrent weals that persist for at least 6 weeks, with or without angioedema. 1 CSU has an estimated point prevalence of approximately 0Á5-1%. 2 Its etiology and pathogenesis has not been completely understood and several causative factors, including autoimmune processes, have been hypothesized. 3, 4 Recent evidence suggests a possible involvement of the coagulation cascade in the pathogenesis of CSU as elevated plasma levels of thrombin and D-dimer were observed in some patients. [5] [6] [7] CSU is a debilitating disease that can severely impact patients' quality of life (QoL). 8, 9 International guidelines recommend second-generation H1-antihistamines at licensed doses as first-line therapy and to progressively increase the dosage up to fourfold, in case of nonresponse. 10 However, in about 10% of patients, H1-antihistamines fail to achieve symptom control even at higher doses and the patient requires additional medication. 9 Omalizumab, a humanized anti-immunoglobulin E (anti-IgE) monoclonal antibody, is recommended as the third-line treatment for CSU, as an add-on to H1-antihistamines. Omalizumab binds to the Fc region of free IgE and prevents it from binding to its highaffinity receptor (FceR1) on mast cells and basophils. 11 The safety and efficacy of omalizumab in the treatment of CSU were established in three phase III studies in patients with H1-antihistamine-refractory moderate-to-severe CSU. [12] [13] [14] In these pivotal studies, disease activity was assessed using the 7-day urticaria activity score (UAS7) as recommended by international guidelines. 10 The UAS7 is a unified and simple score that combines daily weal count and pruritus intensity. Although UAS7 is a useful and widely used tool, it has some limitations in that it is prospective, does not cover angiooedema and is difficult to evaluate if the patient forgets to complete the diary on a daily basis. 15 Hence, the urticaria control test (UCT), a reliable and brief tool, was developed to overcome the limitations of UAS7. The UCT is the first validated and reliable patient-reported outcome (PRO) tool that retrospectively measures disease control in patients with all types of chronic urticaria and through its clear threshold of ≥ 12 for well-controlled disease helps treatment decisions. Unlike UAS7, UCT has a 4-week recall period and is independent of any previous patient presentations. 15 The SUNRISE study was conducted to evaluate the efficacy of subcutaneous (s.c.) omalizumab 300 mg every 4 weeks in French adult patients with CSU who had an inadequate response to H1-antihistamine treatment. The recently validated UCT was used to assess disease activity for the first time in this prospective clinical study. Additionally, the present study explored the relation between plasma D-dimer concentrations and disease activity in patients with CSU.
Materials and methods
Study design and participants SUNRISE (trial registration: EudraCT no. 2014-005424-97) was a prospective, open-label, single-arm, nonrandomized, multicentre (30 centres), phase IV study conducted in France. The study comprised a screening period, a 12-week treatment period and an extension period (Fig. 1) . Patients included in the study were aged between 18 and 75 years and met all the following criteria prior to enrolment: a diagnosis of CSU for ≥ 6 months with an inadequate response to nonsedating H1-antihistamines as evidenced by the presence of hives associated with itching for at least six consecutive weeks at any time before enrolment despite current use of H1-antihistamines; a UAS7 ≥ 16 (equivalent to moderate-to-severe CSU symptoms) and a UCT score < 8. Exclusion criteria included body weight < 40 kg (minimum age at inclusion, 18 years); a clearly defined underlying cause for chronic urticaria (e.g. physical urticaria); use of any H2-antihistamine or leukotriene receptor antagonist within 7 days preceding the screening; presence of other diseases with similar signs of urticaria or angioedema; evidence of parasitic infection and concomitant use of ciclosporin or any other immunosuppressive agent within 30 days prior to screening. The detailed exclusion criteria and the list of prohibited medications are provided in Supplementary Appendix S1 (see Supporting Information).
Enrolled patients were stratified 1 : 2 (with angiooedema : without angioedema) to represent general CSU epidemiology. All patients received three s.c. injections of omalizumab 300 mg (two injections of 150 mg each in the deltoid region of the left and right arm or in the thigh) at 4-week intervals at the study centre. Patients who had an adequate response to omalizumab at Week 12 (defined as UCT ≥ 8 or a UAS7 < 16 at 12 weeks or an improvement > 10 points on the UAS7 between baseline and 12 weeks) were allowed to continue treatment during the extension period (up to commercial availability of omalizumab in France: 3 Nov 2015).
All patients provided written informed consent. The study protocol and all amendments were reviewed and approved by an Independent Ethics Committee. The study was conducted according to the ethical principles of the Declaration of Helsinki.
Study objectives
The primary objective of the study was to evaluate the proportion of patients with a UCT score ≥ 12 (indicating a well-controlled urticaria) at Week 12. The secondary and exploratory objectives have been described in Supplementary Appendix S2 (see Supporting Information).
Study assessments
All the PRO tools used by the patients were available in a French version. The use of the available French version of the UCT was permitted with fees to Moxie GmbH, Berlin, Germany, owners of the rights, for this study. The UCT was completed by the patients at baseline and prior to administration of the study drug at Weeks 4, 8 and 12. The UCT score was derived from four questions, each with five answer options (scored 0-4 points), where low points indicated high disease activity and poor disease control (see Supplementary Appendix S3, Supporting Information, for the UCT questionnaire). The minimum and maximum UCT scores were 0 and 16, respectively, with 16 indicating complete disease control. Patients completed a diary that covered the UAS7 and angioedema activity score (AAS; in case of angioedema), once daily. The diary was given to patients on Day À7, and complete diary information was collected for the seven consecutive days prior to the baseline visit and at Weeks 4, 8 and 12. The QoL assessments were performed at baseline and prior to administration of the study drug at Weeks 4, 8 and 12. See Supplementary Appendix S4 for details on UAS7, AAS, Dermatology Life Quality Index (DLQI), chronic urticaria QoL (CU-QoL) and angioedema QoL (AE-QoL) assessments; see Supporting Information.
The D-dimer concentration was determined at baseline and Weeks 4 and 8. Blood levels of prothrombin factors 1 and 2, hypersensitive C-reactive protein, and factors VIIa and XIIa were also assessed. Safety assessments consisted of collecting all adverse events (AEs) and serious AEs along with their severity and relationship to the study drug.
Statistical analysis
The sample size was based on the proportion of patients with a UCT score ≥ 12 for the full analysis set (FAS), assuming a mean UCT score of 14 with a SD of 3, which corresponds to an expected true proportion of 74Á8% of patients achieving disease control at 12 weeks. Based on a 95% confidence interval (CI), 110 patients were needed to achieve a disease control success rate in the 66Á6-82Á9% range. Based on an assumption that 10% of patients would not contribute values to the primary evaluation, 126 patients were planned to be enrolled. All efficacy analyses were performed using a two-sided test at 5% significance level. The primary analysis variable was the proportion of patients achieving disease control (UCT score ≥ 12).
The proportion of patients achieving disease control at Week 12 was calculated and presented with corresponding 95% CIs using the Clopper-Pearson method (exact binomial). Success of disease control was considered to have been achieved if the observed proportion of patients achieving disease control at Week 12 fell within the 66Á6-82Á9% range. Missing UCT scores at Week 12 were imputed using the lastobservation-carried-forward method. The correlation between D-dimer concentration at baseline and the UCT score and UAS7 at Week 8 was presented using Spearman's rank correlation coefficient and scatter plots. The FAS, which included all patients who provided signed informed consent and received at least one dose of omalizumab, was used to analyse the efficacy and safety data.
Results
Of the 156 patients screened, 136 were enrolled and received at least one dose of omalizumab; 124 patients completed the core period of 12 weeks, and 12 patients discontinued the study (Fig. 2) . The most common reason for discontinuation was protocol deviation (n = 6, 4Á4%, Fig. 2 ). The mean (AE SD) age of the study population was 44Á4 AE 12Á7 years and women comprised 77Á9% of this population ( Table 1) . The median (range) number of previous CSU medications was 2Á0 (1-5) (Table 2) ; the most frequent were H1-antihistamines and antileukotrienes. During the study, 50Á7% of patients used at least one concomitant medication for CSU. The most common category of concomitant medications (taken by 59Á6% of patients) was second-generation antihistamines (Table 3) .
Urticaria control test score and 7-day urticaria activity score
The primary endpoint of disease control (UCT score ≥ 12 at Week 12) was achieved by 74Á6% (95% CI 66Á4-81Á7) of patients (Fig. 3 ). There was a significant increase in the UCT score from baseline to Week 12, with a mean increase of 9Á6 AE 4Á95 points (P < 0Á0001) indicating a better disease control (Fig. 4) . The increase in the UCT score was comparable between patients with and without angioedema. A total of 67Á7% of patients (95% CI 58Á8-75Á7) achieved a UAS7 ≤ 6 at Week 12 ( Fig. 3) , with no major differences between patients with and without angioedema. There was a significant improvement in UAS7 from baseline to Week 12 (À22Á9 AE 11Á67 points, P < 0Á0001), signifying the efficacy of omalizumab treatment in patients with CSU. The decrease in the UAS7 was comparable between patients with and without angioedema (Fig. 4) . There was a strong negative correlation between the UCT score and UAS7 at Week 12 (Spearman's correlation coefficient À0Á839; Fig. 5a ). Overall, in 87Á3% of patients, both UCT score and UAS7 varied in a coherent and consistent manner (UCT ≥ 12 and UAS7 ≤ 6 or UCT < 12 and UAS7 > 6), reinforcing the association between the two scores (Fig. 5b) .
D-dimer and other biomarkers
The mean plasma concentration of D- ) (Fig. 6 ). The reduction in plasma D-dimer levels with omalizumab was observed both in patients with and without angioedema at baseline (Fig. 6 ). There was a weak positive correlation of UCT score at Week 12 with baseline D-dimer concentration (Spearman's correlation coefficient 0Á059) and a weak negative Patients with UAS7 ≤ 6 52·0% 64·2% 67·7%
(a) Fig 3 . Proportion of patients with well-controlled urticaria at Week 12 (a) UCT score ≥ 12 and (b) UAS7 ≤ 6. UAS, 7-day urticaria activity score; UCT, urticaria control test. Error bars represent the confidence interval. UAS, 7-day urticaria activity score; UCT, urticaria control test.
correlation of UAS7 at Week 12 with baseline D-dimer concentration (Spearman's correlation coefficient À0Á108) (Fig. 7) . Ten patients had a very high baseline D-dimer level (> 3000 ng mL À1 ), in five of those the D-dimer levels were normalized with treatment at Week 8. At Week 12, eight patients had a UAS7 ≤ 6 and seven of nine patients, who had a UCT score available at Week 12, achieved a UCT score ≥ 12.
No meaningful correlation with PROs was demonstrated for the other biomarkers.
Quality of life
There was a notable improvement in the QoL of patients with CSU after 12 weeks of omalizumab treatment. Although patients with angioedema had higher CU-QoL and DLQI scores at baseline than those without angioedema, the improvement in scores was similar in both groups at Week 12 (Table 4) after treatment with omalizumab. The UCT score was negatively correlated with CU-QoL and DLQI scores at Week 12 (Table 5) .
Angioedema-related assessments
In patients with angioedema, the total AE-QoL score decreased and the AAS improved from baseline to Week 12 with omalizumab (both P < 0Á0001; Table 4 ). The UCT score was negatively correlated with AE-QoL and AAS at Week 12 (Table 5) .
Safety
The mean duration of exposure to omalizumab during the core treatment period was 11Á93 AE 1Á72 (range 4Á1-14Á1) weeks. Most patients (93Á4%) received a total of three injections as the approved dose of 300 mg was administered s.c. every 4 weeks over a period of 3 months, and the mean cumulative dose was 869Á12 AE 122Á63 mg. The mean duration of exposure to omalizumab was 19Á11 AE 5Á46 (range 4Á1-29Á1) weeks from baseline up to the end of the study. No death or episode of anaphylactic shock were reported during the study. A total of five patients reported seven serious AEs which included pneumonia, cervical vertebral fracture, fractured sacrum, ligament sprain, obesity, bladder dilatation and pharyngeal oedema.
During the 12 weeks of treatment, 66Á2% of patients experienced at least one AE and 36Á8% of patients experienced at least one treatment-related AE. The most common treatment-emergent AEs were headache (15Á4%), asthenia (14Á7%) and arthralgia (7Á4%) ( Table 6 ).
Discussion
The results of the SUNRISE study confirm the efficacy of omalizumab 300 mg s.c. in controlling the symptoms and in improving the QoL in French patients with moderate-to-severe CSU nonresponsive to H1-antihistamine treatment. Indeed, two-thirds of our patients achieved a UAS7 ≤ 6 at Week 12 of omalizumab treatment, indicative of well-controlled disease, which is comparable with the data observed in the three pivotal studies (52-66% of patients with a UAS7 ≤ 6). [12] [13] [14] SUNRISE is the first prospective study that investigated the utility of the UCT in patients with CSU treated with omalizumab. Overall, 74Á6% of patients in our study achieved a UCT score ≥ 12 with omalizumab treatment. Our results confirm that the UCT is a reliable tool to measure disease control, consistent with the findings from a previous study from Thailand in 169 patients with chronic urticaria. 18 Urticaria symptoms vary greatly from one day to another, and the disease condition at the time of presentation to the physician is rarely representative of actual disease status. 15 Therefore, it is important to have retrospective, easy-to-use PRO tools such as the UCT. Taken together, the UAS7 and UCT scores confirm the efficacy of omalizumab in these patients with moderate-to-severe CSU nonresponsive to H1-antihistamines. Interestingly, a significant negative correlation was observed between the UCT score and UAS7, with a consistent variation between the two scores in a majority of patients, reinforcing the correlation between the two.
Another interesting finding is that omalizumab was equally efficacious in patients with or without angioedema as shown by the comparable change in UCT score and UAS7 in both groups at Week 12. Angioedema is fairly common in patients with CSU (33-67%); it adversely affects the patient's QoL and is also associated with increased disease duration and worse prognosis. 2 In the present study, 61% of patients had angioedema at baseline with an increased AE-QoL total score, which significantly decreased at Week 12 along with the AAS. These results are in line with the findings of the X-ACT study, which showed the efficacy of omalizumab in patients with moderateto-severe CSU symptoms and angioedema nonresponsive to high doses of antihistamine treatment. 19 In addition, as expected, our patients had a severe QoL impairment at baseline as evidenced by the high CU-QoL, DLQI and AE-QoL scores. Treatment with omalizumab for 12 weeks resulted in a significant improvement of all QoL scores. Moreover, these scores negatively correlated with the UCT scores, further confirming the reliability of the UCT. Overall, these results from the SUNRISE study suggest that UCT can be used as an alternative to UAS7, for example, in new patients or in those who did not fill in their UAS7 before the consultation and in patients with angioedema whose disease activity cannot be measured by UAS7. Several pathways have been suggested to explain omalizumab's mechanism of action in urticaria; however, the mechanism is not yet fully understood. The major effect of omalizumab in patients with CSU is considered to result from 
AAS, angioedema activity score; AE-QoL, angioedema QoL; CU-QoL, chronic urticaria QoL; DLQI, Dermatology Life Quality Index; QoL, quality of life.
a Assessed in patients with angioedema.
b Absolute change from baseline at Week 12 was not calculated for DLQI Recently, Asero et al. observed elevated baseline D-dimer levels in 59% of patients with severe CSU, and a dramatic decrease in the levels in some patients who responded to omalizumab treatment, suggesting a possible effect of omalizumab on coagulation activation and fibrin degradation in a subset of patients with CSU. 7 Consistent with the published literature, elevated baseline D-dimer levels were observed in patients from the SUNRISE study. A fast normalization in plasma D-dimer levels was observed with omalizumab as early as Week 4, with a further decrease until Week 8. There was no meaningful correlation between Week 12 UCT or UAS7 scores and baseline D-dimer concentrations. However, in a small subset of patients (10 of 136) with very high baseline D-dimer levels (> 3000 ng mL This study has some limitations including its open-label nature and lack of a control group. Although H1-antihistamine treatment was to be at a stable dose for the duration of the treatment period per protocol, patients had the option to decrease the dosage if needed. As any change in dose was not actively monitored, we cannot conclude on the adaptation of the H1-antihistamine following improvement in urticaria. Moreover, the study was conducted only in France, possibly limiting the generalizability of the results. Overall, these data further confirm the efficacy of omalizumab in patients with CSU with inadequate response to H1-antihistamine treatment and highlight the reliability of the UCT as a disease control tool in these patients. Omalizumab was well tolerated, and the safety results were consistent with the established safety profile.
The use of the UCT should be recommended in routine clinical practice in order to assess efficacy and response to any urticaria treatment. Results demonstrate that D-dimers are elevated in some patients and change in response to treatment. This study does not support the usefulness of D-dimer as a marker of disease activity in adult urticaria; however, it may represent a useful tool to indicate patients who respond to omalizumab.
